Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
| 385.57 Delayed Data As of Jan 16 |  -5.18 / -1.33%Today’s Change | 271.37 Today|||52-Week Range 442.00 | +2.69% Year-to-Date |
Latest REGN News | Press Releases
| Eli Lilly to Boost Its Dermatology Pipeline with $1.1 Billion Dermira Acquisition Jan 10 / MotleyFool.com - Paid Partner Content | Why the FDA's Decision on Aimmune's Peanut Allergy Drug Is Crucial for the Company -- and Patients Jan 09 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 390.75 |
| Today’s open | 393.17 |
| Day’s range | 381.82 - 394.00 |
| Volume | 620,517 |
| Average volume (3 months) | 744,143 |
| Market cap | $41.2B |
Data as of 4:00pm ET, 01/16/2020
Growth & Valuation
| Earnings growth (last year) | +100.98% |
| Earnings growth (this year) | +6.04% |
| Earnings growth (next 5 years) | +8.00% |
| Revenue growth (last year) | +14.28% |
| P/E ratio | 20.6 |
| Price/Sales | 6.39 |
| Price/Book | 4.75 |
Competitors
| ---- | ||
| ALXNAlexion Pharmaceutic... | -0.02 | -0.02% |
| VRTXVertex Pharmaceutica... | +1.35 | +0.58% |
| TAKTakeda Pharmaceutica... | +0.04 | +0.20% |
Data as of 6:30pm ET, 01/16/2020
Financials
| Next reporting date | February 11, 2020 |
| EPS forecast (this quarter) | $7.19 |
| Annual revenue (last year) | $6.7B |
| Annual profit (last year) | $2.4B |
| Net profit margin | 36.42% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Tarrytown, New York |
Forecasts
